跳转至内容
Merck
CN
  • Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces.

Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces.

Hepatology (Baltimore, Md.) (2014-08-22)
Douglas A Simonetto, Hui-yin Yang, Meng Yin, Thiago M de Assuncao, Jung Hee Kwon, Moira Hilscher, Shuchong Pan, Liu Yang, Yan Bi, Arthur Beyder, Sheng Cao, Robert D Simari, Richard Ehman, Patrick S Kamath, Vijay H Shah
摘要

Chronic passive hepatic congestion (congestive hepatopathy) leads to hepatic fibrosis; however, the mechanisms involved in this process are not well understood. We developed a murine experimental model of congestive hepatopathy through partial ligation of the inferior vena cava (pIVCL). C57BL/6 and transgenic mice overexpressing tissue factor pathway inhibitor (SM22α-TFPI) were subjected to pIVCL or sham. Liver and blood samples were collected and analyzed in immunohistochemical, morphometric, real-time polymerase chain reaction, and western blot assays. Hepatic fibrosis and portal pressure were significantly increased after pIVCL concurrent with hepatic stellate cell (HSC) activation. Liver stiffness, as assessed by magnetic resonance elastography, correlated with portal pressure and preceded fibrosis in our model. Hepatic sinusoidal thrombosis as evidenced by fibrin deposition was demonstrated both in mice after pIVCL as well as in humans with congestive hepatopathy. Warfarin treatment and TFPI overexpression both had a protective effect on fibrosis development and HSC activation after pIVCL. In vitro studies show that congestion stimulates HSC fibronectin (FN) fibril assembly through direct effects of thrombi as well as by virtue of mechanical strain. Pretreatment with either Mab13 or Cytochalasin-D, to inhibit β-integrin or actin polymerization, respectively, significantly reduced fibrin and stretch-induced FN fibril assembly. Chronic hepatic congestion leads to sinusoidal thrombosis and strain, which in turn promote hepatic fibrosis. These studies mechanistically link congestive hepatopathy to hepatic fibrosis.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
十二烷基硫酸钠, BioReagent, suitable for electrophoresis, Molecular Biology, ≥98.5% (GC)
Sigma-Aldrich
十二烷基硫酸钠, ≥99.0% (GC), dust-free pellets
Sigma-Aldrich
十二烷基硫酸钠, ACS reagent, ≥99.0%
Sigma-Aldrich
十二烷基硫酸钠 溶液, BioUltra, Molecular Biology, 10% in H2O
Sigma-Aldrich
十二烷基硫酸钠, ReagentPlus®, ≥98.5% (GC)
Sigma-Aldrich
十二烷基硫酸钠, BioUltra, Molecular Biology, ≥99.0% (GC)
Sigma-Aldrich
十二烷基硫酸钠 溶液, BioUltra, 20% in H2O
Supelco
十二烷基硫酸钠, dust-free pellets, suitable for electrophoresis, Molecular Biology, ≥99.0% (GC)
Supelco
十二烷基硫酸钠, suitable for ion pair chromatography, LiChropur, ≥99.0%
Sigma-Aldrich
十二烷基硫酸钠, BioXtra, ≥99.0% (GC)
Sigma-Aldrich
十二烷基硫酸钠, ≥98.0% (GC)
Sigma-Aldrich
十二烷基硫酸钠, 92.5-100.5% based on total alkyl sulfate content basis
Sigma-Aldrich
十二烷基硫酸钠, ≥90% ((Assay))
Sigma-Aldrich
十二烷基硫酸钠, tested according to NF, mixture of sodium alkyl sulfates consisting mainly of sodium dodecyl sulfate
Sigma-Aldrich
二喹啉甲酸 二钠盐 水合物, ≥98% (HPLC)
Sigma-Aldrich
21-Hydroxyprogesterone, ≥97% (HPLC)
月桂基硫酸钠, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
十二烷基硫酸钠, BioReagent, suitable for electrophoresis, Molecular Biology, ≥98.5% (GC), free-flowing, Redi-Dri
Sigma-Aldrich
十二烷基硫酸钠, Vetec, reagent grade, ≥98%
Sigma-Aldrich
二喹啉甲酸 二钠盐 水合物, Vetec, reagent grade, 98%